FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099349054> ?p ?o ?g. }

• W2099349054 endingPage "1502" @default.
• W2099349054 startingPage "1499" @default.
• W2099349054 abstract "The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.Twenty-nine patients with PPCL were collected. Bortezomib was given at standard doses and schedules, in various combinations with dexamethasone, thalidomide, doxorubicin, melphalan, prednisone, vincristine, and cyclophosphamide.An overall response rate of 79% was observed, with 38% of at least very good partial remission. Grade 3-4 hematological, neurological, infectious, and renal toxic effects occurred in 20%, 21%, 16%, and 4% of patients, respectively. After a median follow-up of 24 months, 16 patients were alive (55%), 12 of whom were in remission phase and 4 relapsed. The best long-term results were achieved in patients who received stem-cell transplantation after bortezomib induction.Bortezomib, used as initial therapy, is able to increase the percentage and the quality of responses in PPCL patients, producing a significant improvement of survival." @default.
• W2099349054 created "2016-06-24" @default.
• W2099349054 creator A5002073636 @default.
• W2099349054 creator A5011614506 @default.
• W2099349054 creator A5012890519 @default.
• W2099349054 creator A5018088213 @default.
• W2099349054 creator A5021802241 @default.
• W2099349054 creator A5030706220 @default.
• W2099349054 creator A5038063975 @default.
• W2099349054 creator A5041148264 @default.
• W2099349054 creator A5042510486 @default.
• W2099349054 creator A5042998256 @default.
• W2099349054 creator A5044869604 @default.
• W2099349054 creator A5046025763 @default.
• W2099349054 creator A5054317101 @default.
• W2099349054 creator A5057593886 @default.
• W2099349054 creator A5059776581 @default.
• W2099349054 creator A5059967673 @default.
• W2099349054 creator A5063836948 @default.
• W2099349054 creator A5077204314 @default.
• W2099349054 date "2012-06-01" @default.
• W2099349054 modified "2023-10-10" @default.
• W2099349054 title "Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party" @default.
• W2099349054 cites W1827273305 @default.
• W2099349054 cites W1965797281 @default.
• W2099349054 cites W1967025604 @default.
• W2099349054 cites W1970547637 @default.
• W2099349054 cites W1984502788 @default.
• W2099349054 cites W2003426156 @default.
• W2099349054 cites W2005811130 @default.
• W2099349054 cites W2014118946 @default.
• W2099349054 cites W2029070213 @default.
• W2099349054 cites W2036322109 @default.
• W2099349054 cites W2042264019 @default.
• W2099349054 cites W2043816863 @default.
• W2099349054 cites W2044436186 @default.
• W2099349054 cites W2046983168 @default.
• W2099349054 cites W2054970678 @default.
• W2099349054 cites W2055744416 @default.
• W2099349054 cites W2062483499 @default.
• W2099349054 cites W2066138044 @default.
• W2099349054 cites W2076416848 @default.
• W2099349054 cites W2087040043 @default.
• W2099349054 cites W2101761743 @default.
• W2099349054 cites W2111566607 @default.
• W2099349054 cites W2115565576 @default.
• W2099349054 cites W2121464444 @default.
• W2099349054 cites W2122623412 @default.
• W2099349054 cites W2128591516 @default.
• W2099349054 cites W2162079046 @default.
• W2099349054 cites W2164807675 @default.
• W2099349054 cites W2166587891 @default.
• W2099349054 cites W2169330510 @default.
• W2099349054 cites W2531434662 @default.
• W2099349054 cites W78262064 @default.
• W2099349054 doi "https://doi.org/10.1093/annonc/mdr480" @default.
• W2099349054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22039089" @default.
• W2099349054 hasPublicationYear "2012" @default.
• W2099349054 type Work @default.
• W2099349054 sameAs 2099349054 @default.
• W2099349054 citedByCount "68" @default.
• W2099349054 countsByYear W20993490542012 @default.
• W2099349054 countsByYear W20993490542013 @default.
• W2099349054 countsByYear W20993490542014 @default.
• W2099349054 countsByYear W20993490542015 @default.
• W2099349054 countsByYear W20993490542016 @default.
• W2099349054 countsByYear W20993490542017 @default.
• W2099349054 countsByYear W20993490542018 @default.
• W2099349054 countsByYear W20993490542019 @default.
• W2099349054 countsByYear W20993490542020 @default.
• W2099349054 countsByYear W20993490542021 @default.
• W2099349054 countsByYear W20993490542022 @default.
• W2099349054 countsByYear W20993490542023 @default.
• W2099349054 crossrefType "journal-article" @default.
• W2099349054 hasAuthorship W2099349054A5002073636 @default.
• W2099349054 hasAuthorship W2099349054A5011614506 @default.
• W2099349054 hasAuthorship W2099349054A5012890519 @default.
• W2099349054 hasAuthorship W2099349054A5018088213 @default.
• W2099349054 hasAuthorship W2099349054A5021802241 @default.
• W2099349054 hasAuthorship W2099349054A5030706220 @default.
• W2099349054 hasAuthorship W2099349054A5038063975 @default.
• W2099349054 hasAuthorship W2099349054A5041148264 @default.
• W2099349054 hasAuthorship W2099349054A5042510486 @default.
• W2099349054 hasAuthorship W2099349054A5042998256 @default.
• W2099349054 hasAuthorship W2099349054A5044869604 @default.
• W2099349054 hasAuthorship W2099349054A5046025763 @default.
• W2099349054 hasAuthorship W2099349054A5054317101 @default.
• W2099349054 hasAuthorship W2099349054A5057593886 @default.
• W2099349054 hasAuthorship W2099349054A5059776581 @default.
• W2099349054 hasAuthorship W2099349054A5059967673 @default.
• W2099349054 hasAuthorship W2099349054A5063836948 @default.
• W2099349054 hasAuthorship W2099349054A5077204314 @default.
• W2099349054 hasBestOaLocation W20993490541 @default.
• W2099349054 hasConcept C126322002 @default.
• W2099349054 hasConcept C141071460 @default.
• W2099349054 hasConcept C143998085 @default.
• W2099349054 hasConcept C167135981 @default.
• W2099349054 hasConcept C2776364478 @default.

• next